Jupiter Endovascular

The conversation continues today at #EuroPCR. Join us this afternoon, Thursday, May 21 at 1:40 PM in Room 243, for our sponsored symposium: “Pulmonary Embolism Intervention: A Turning Point in Defining Success.” A panel of leading SPIRARE II investigators from Europe and the U.S. will discuss how the field is evolving in light of the new 2026 AHA/ACC PE guidelines and HI-PEITHO results, and what Transforming Fixation (TFX)-enabled thrombectomy means for the next phase of PE care.

Today we announced a major milestone for Jupiter Endovascular and for the treatment of pulmonary embolism. Pivotal results from the SPIRARE II trial, presented by Dr. Catalin Toma at #EuroPCR, showed that the Vertex™ Pulmonary Embolectomy System met both primary endpoints, demonstrating meaningful heart recovery and clinical safety, and paired invasive hemodynamics documented the full physiologic impact of TFX-enabled thrombectomy. Read the full release here: https://lnkd.in/gtY3VF7n Our deepest gratitude goes to the investigators, site teams, and most of all the patients whose participation made this study possible. The Vertex™ Pulmonary Embolectomy System is for investigational use only.

Join us today at #EuroPCR, as Dr. Catalin Toma takes the stage in the Innovation Theatre to present the late-breaking pivotal results from SPIRARE II. We look forward to sharing these data.

Heading to #EuroPCR? Jupiter Endovascular has two sessions you won't want to miss. On Wednesday, May 20 at 3:00 PM in the Innovation Theatre, Dr. Catalin Toma will present the late-breaking pivotal results from the SPIRARE II trial, a major milestone for Transforming Fixation (TFX) and the treatment of pulmonary embolism. The following day, Thursday, May 21 at 1:40 PM in Room 243, join our sponsored symposium: "Pulmonary Embolism Intervention: A Turning Point in Defining Success." A panel of leading SPIRARE II investigators from Europe and the U.S. will discuss the evolving PE landscape in the context of the new 2026 AHA/ACC guidelines and emerging randomized data. We look forward to seeing you there.

We were honored to host Deborah K. - Partner at Sonder Capital and Jupiter Endovascular Board Director - for an International Women’s Day #IWD2026 conversation on leadership and company building. Deb shared valuable insights on what she looks for in successful companies, highlighting the power of team synergy, open communication, and aligned values. She also reminded us that asking for help is a strength, and that great organizations thrive when people learn from and support one another. Thank you Deb for your leadership and inspiration. *The Vertex Pulmonary Embolectomy System is for investigational use only.

Heading to #CRT2026 in DC this weekend? Jupiter Endovascular Chief Science Officer Chuck Love will present our Transforming Fixation (TFX) technology on Monday 3:53 PM as our entry into the CRT Best Innovations Competition. We hope to see you there!

Jupiter Endovascular has completed enrollment in the SPIRARE II pivotal trial evaluating the Vertex™ Pulmonary Embolectomy System with Transforming Fixation (TFX). This milestone represents more than a year of focused clinical execution across four countries and reflects the culmination of nearly a decade of unwavering innovation to develop a technology with the potential to redefine therapies in complex cardiovascular anatomies. We would like to recognize and thank Dr. Catalin Toma and Dr. Sameh Sayfo, MD, MBA, FACC, FSCAI for their leadership as the trial Global Co-PIs, Dr. Vikas Aggarwal and the team at Henry Ford Health for enrolling the final patient, and the physicians, researchers, and patients whose participation made this pivotal study possible. Read the full press release: https://lnkd.in/e25HdCcW *The Vertex Pulmonary Embolectomy System is for investigational use only.

Our CEO Carl St. Bernard recently joined Tom Salemi on the DeviceTalks podcast for a wide-ranging discussion on leadership and innovation. Carl reflects on his career, the vision behind Transforming Fixation (TFX) technology, what it means for pulmonary embolism and cardiovascular disease, and what’s ahead for Jupiter Endovascular. Thanks Tom and #DeviceTalks for the conversation. Well worth a listen.

We’re thrilled to announce that Jupiter has been honored with Mployer’s 2025 Top Benefits Award, recognizing organizations that set the standard in medical, ancillary, leave, and retirement programs. This achievement isn’t just about benefits, it’s about our unwavering commitment to supporting every dimension of our employees’ lives. At Jupiter, we believe that innovation begins with the people behind it. That’s why our approach to benefits goes beyond traditional offerings. We focus on whole-person wellbeing - physical, emotional, financial, and social - because when our team feels cared for and empowered, they can do their best work for our patients and for each other. Mployer’s independent, data-driven evaluation benchmarks employers by industry, region, and size, making this recognition especially meaningful. It validates our belief that a thriving workplace starts with holistic support, from career growth and mental health resources to flexible leave and retirement security. This award reflects our mission: to rewrite the rules of endovascular medicine by creating an environment where people feel valued, connected, and equipped to excel. Supporting our team isn’t just a priority; it’s the foundation of the innovation, execution, and patient impact we strive for every day. Ready to make an impact? At Jupiter, we don’t just look for “fit”, we look for people who help us grow and live our values every day. Join a team that values cultural contribution, whole-person wellbeing, and innovation.  👉 Careers at Jupiter: https://lnkd.in/exCrQG6T

As part of our annual holiday giving drive, the Jupiter Endovascular team came together these past few weeks to donate essential goods to Serenity House Oakland, a nonprofit dedicated to supporting women affected by domestic violence and those reentering society post-incarceration. We are proud of our employees for living our values beyond the workplace and making a tangible difference in our community this holiday season. Thank you to Serenity House for the critical work you do every day, and to our team for their generosity and compassion.